The β3-adrenergic agonist CL316,243 inhibits insulin signaling but not glucose uptake in primary human adipocytes

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 8, 2005, Pages 418-422

  Jost, Marco M ^a   Jost, P ^b   Klein, J ^c   Klein, H H ^d  

^a BioVisioN AG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Insulin receptor; Obesity; PD151746; PI3 kinase; Protein kinase B

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; INSULIN; INSULIN RECEPTOR KINASE; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 1,3 DIOXOLANE DERIVATIVE; ACRYLIC ACID DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; PD 151746;

ADIPOCYTE; ARTICLE; BREAST CELL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; INSULIN RESISTANCE; METABOLISM; MORTALITY; OBESITY; PHYSIOLOGY;

ACRYLATES; ADIPOCYTES; ADRENERGIC BETA-AGONISTS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; DIOXOLES; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 25444459674     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865771     Document Type: Article

References (34)

1. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 1996; 15: 6541-6551
2. Arch JR. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 2002; 440: 99-107
3. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti- obesity drugs. Nature 1984; 309: 163-165
4. Collins S, Cao W, Kiefer W, Dixon T, Medvedev A, Onuma H, Surwit R. Adrenoceptors, uncoupling proteins, and energy expenditure. Experimental Biol Med 2001; 226: 982-990
5. De Matteis R, Arch J, Petroni M, Ferrari D, Cinti S, Stock M. Immunohistochemical identification of the beta(3)-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int J Obes Relat Metab Disord 2002; 26: 1442-1450
6. de Souza C, Burkey B. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des 2001; 7: 1433-1449
7. Ghorbani M, Himms-Hagen J. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes Relat Metab Disord 1997; 21: 465-475
8. Grujic D, Susulic VS, Harper ME, Himms-Hagen J, Cunningham BA, Corkey BE, Lowell BB. beta 3-adrenergic receptors on white and brown adipocytes mediate beta 3-selective agonis-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J Biol Chem 1997; 272: 17686-17693
9. 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes 1996; 20: 428-434
10. 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. Prog Med Chem 2003; 41: 167-194
11. Jost P, Fasshauer M, Kahn C, Benito M, Meyer M, Ott V, Lowell B, Klein H, Klein J. Atypical β-adrenergic effects on insulin signaling and action in β3-adrenoceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab 2002; 283: E146-E153
12. Kitamura T, Ogawa W, Sakaue H. Requirement for activation of the serine-threonine kinase akt (Protein kinase B) in insulin stimulation of protein synthesis but not glucose transport. Mol Cell Biol 1998; 18: 3708-3717
13. Klein HH, Kowalewski B, Drenckhan M, Neugebauer S, Matthaei S, Kotzke G. A microtiter well assay system to measure insulin activation of insulin receptor kinase in intact human mononuclear cells. Diabetes 1993; 42: 883-890
14. Klein HH, Matthaei S, Drenkhan M, Ries W, Scriba PC. The relationship between insulin binding, insulin activation of insulin-receptor tyrosine kinase, and insulin stimulation of glucose uptake in isolated rat adipocytes. Effects of isoprenaline. Biochem J 1991; 274: 787-792
15. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 1995; 44: 1310-1317
16. Klein J, Fasshauer M, Benito M, Kahn CR. Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. Mol Endocrinol 2000; 14: 764-773
17. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR. beta 3-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 1999; 274: 34795-34802
18. Krief S, Lonnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, Strosberg AD, Ricquier D, Emorine LJ. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993; 91: 344-349
19. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-2910
20. Linder K, Arner P, Flores-Morales A, Tollet-Egnell P, Norstedt G. Differentially expressed genes in visceral or subcutaneous adipose tissue of obese men and women. J Lipid Res 2004; 45: 148-154, Epub 2003 Oct, 2016
21. Liu YF, Herschkovitz A, Boura-Halfon S, Ronen D, Paz K, Leroith D, Zick Y. Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Mol Cell Biol 2004; 24: 9668-9681
22. Lowell B, Flier J. Brown adipose tissue, b3-adrenergic receptors, and obesity. Annu Rev Med 1997; 48: 307-316
23. Meyer M, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, Klein HH. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 2002; 51: 2691-2697
24. Moeschel K, Beck A, Weigert C, Lammers R, Kalbacher H, Voelter W, Schleicher ED, Haring HU, Lehmann R. Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem 2004; 279: 25157-25163
25. Nicholls D, Locke R. Thermogenic mechanisms in brown fat. Physiol Rev 1984; 64: 1-64
26. Rondinone CM, Carvalho E, Wesslau C, Smith UP. Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus. Diabetologia 1999; 42: 819-825
27. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1997; 94: 4171-4175
28. Smith U. Importance of the regional distribution of the adipose tissue-concluding remarks. Acta Med Scand Suppl 1988; 723: 233-236
29. Strosberg A. Towards the development and use of human-selective agonists for the pharmacologic treatment of obesity and diabetes. J Endocrinol 1997; 155
30. Wang KKW, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I, Probert Jr. AW, Marcoux FW, Ye Q, Takano E, Hatanaka M, Maki M, Caner H, Collins JL, Fergus A, Lee KS, Lunney EA, Hays SJ, Yuen PW. An alpha-mercaptoacrylic acid derivative is a selective non-peptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA 1996; 93: 6687-6692
31. Weyer C, Tataranni P, Snitker S, Danforth E, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998; 47: 1555-1561
32. Whiteman EL, Cho H, Birnbaum MJ: Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002; 13: 444-451
33. Wu X, Hoffstedt J, Deeb W, Singh R, Sedkova N, Zilbering A, Zhu L, Park PK, Arner P, Goldstein BJ. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab 2001; 86: 5973-5980
34. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602